Skip to main content
Journal cover image

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Publication ,  Journal Article
Lee, T-H; Tillmann, HL; Patel, K
Published in: Mol Diagn Ther
February 2014

Hepatitis C virus—a major global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma—affects millions of people worldwide. Pegylated interferon (Peg-IFN) and ribavirin (RBV) had been the standard treatment for a decade until availability of the protease inhibitors in 2011. However, current antiviral therapy is still IFN-based and is associated with significant side effects and variable treatment response. Thus, various host and viral factors have been evaluated before and during treatment for the prediction of sustained virologic response to antiviral therapy. In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-λ3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Additionally, inosine triphosphatase (ITPA) gene variants were found to be associated with RBV-induced hemolytic anemia, which could affect treatment dose for selected patients. IL28B, ITPA, and other treatment predictors allowed for a potential individualized approach to treat hepatitis C. In the era of increased overall virologic response rates and good tolerability of the rapidly developing non-IFN oral direct-acting antiviral therapy regimens, the need for individualized treatment is likely to diminish. Various predictors of response, including IL28B will likely be of reduced importance in the near future.

Duke Scholars

Published In

Mol Diagn Ther

DOI

EISSN

1179-2000

Publication Date

February 2014

Volume

18

Issue

1

Start / End Page

25 / 38

Location

New Zealand

Related Subject Headings

  • Ribavirin
  • Pyrophosphatases
  • Protease Inhibitors
  • Precision Medicine
  • Polymorphism, Single Nucleotide
  • Pharmacology & Pharmacy
  • Oncology & Carcinogenesis
  • Interleukins
  • Interferons
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, T.-H., Tillmann, H. L., & Patel, K. (2014). Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. Mol Diagn Ther, 18(1), 25–38. https://doi.org/10.1007/s40291-013-0053-4
Lee, Tzu-Hao, Hans L. Tillmann, and Keyur Patel. “Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Mol Diagn Ther 18, no. 1 (February 2014): 25–38. https://doi.org/10.1007/s40291-013-0053-4.
Lee, Tzu-Hao, et al. “Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Mol Diagn Ther, vol. 18, no. 1, Feb. 2014, pp. 25–38. Pubmed, doi:10.1007/s40291-013-0053-4.
Journal cover image

Published In

Mol Diagn Ther

DOI

EISSN

1179-2000

Publication Date

February 2014

Volume

18

Issue

1

Start / End Page

25 / 38

Location

New Zealand

Related Subject Headings

  • Ribavirin
  • Pyrophosphatases
  • Protease Inhibitors
  • Precision Medicine
  • Polymorphism, Single Nucleotide
  • Pharmacology & Pharmacy
  • Oncology & Carcinogenesis
  • Interleukins
  • Interferons
  • Humans